Amy H. Peterman
YOU?
Author Swipe
View article: “Pathways”: A hope‐enhancing intervention for patients undergoing treatment for advanced lung cancer
“Pathways”: A hope‐enhancing intervention for patients undergoing treatment for advanced lung cancer Open
(249/250) Objective Observational data suggest hope is associated with the quality of life and survival of people with cancer. This trial examined the feasibility, acceptability, and preliminary outcomes of “Pathways,” a hope intervention …
View article: Characterizing changes in mental health‐related outcomes for health service psychology graduate students during the first year of the COVID‐19 pandemic
Characterizing changes in mental health‐related outcomes for health service psychology graduate students during the first year of the COVID‐19 pandemic Open
Objectives Health service psychology (HSP) graduate students experienced adverse mental health outcomes during COVID‐19. However, little is known about how mental health outcomes changed in this population after the onset of COVID‐19. Meth…
View article: A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer Open
INTRODUCTION: Single-agent gemcitabine is a standard of care for elderly patients with advanced non-small cell lung cancer, but novel therapies are needed for this patient population. METHODS: We performed a noncomparative randomized phase…
View article: A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer Open
In a multicenter randomized phase II trial of gemcitabine (arm A), erlotinib (arm B), and gemcitabine and erlotinib (arm C), similar progression-free survival (PFS) and overall survival (OS) were observed in all arms. We performed an explo…
View article: Developing pathways, a hope‐enhancing intervention for metastatic lung cancer patients receiving cancer treatment
Developing pathways, a hope‐enhancing intervention for metastatic lung cancer patients receiving cancer treatment Open
Objective Between 40% and 65% of lung cancer patients report concern about maintaining valued activities and roles, yet few interventions address this concern. Hope, a patient's perceived ability to generate goals and identify ways to purs…
View article: TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases Open
Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule …